Related Experiment Video
Updated: Nov 25, 2025
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Mumefural Improves Blood Flow in a Rat Model of FeCl3-Induced Arterial Thrombosis
Jihye Bang1,2, Won Kyung Jeon1,2
1Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, Korea.
Abstract:
Mumefural (MF), a bioactive component of the processed fruit of Prunus mume Sieb. et Zucc, is known to inhibit platelet aggregation induced by agonists in vitro. In this study, we investigated the anti-thrombotic effects of MF using a rat model of FeCl3-induced arterial thrombosis. Sprague-Dawley rats were intraperitoneally injected with MF (0.1, 1, or 10 mg/kg) 30 min before 35% FeCl3 treatment to measure the time to occlusion using a laser Doppler flowmeter and to assess the weight of the blood vessels containing thrombus. MF treatment significantly improved blood flow by inhibiting occlusion and thrombus formation. MF also prevented collagen fiber damage in injured vessels and inhibited the expression of the platelet activation-related proteins P-selectin and E-selectin. Moreover, MF significantly reduced the increased inflammatory signal of nuclear factor (NF)-κB, toll-like receptor 4 (TLR4), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in blood vessels. After administration, MF was detected in the plasma samples of rats with a bioavailability of 36.95%. Therefore, we suggest that MF may improve blood flow as a candidate component in dietary supplements for improving blood flow and preventing blood circulation disorders.
Insights
Mumefural (MF), derived from Prunus mume, effectively prevents blood clots and improves circulation. This study shows MF inhibits thrombosis and reduces inflammation, suggesting its potential as a dietary supplement for vascular health.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Natural Product Chemistry
Background:
- Mumefural (MF) is a bioactive compound from processed Prunus mume fruit.
- MF has demonstrated in vitro inhibition of platelet aggregation.
- Arterial thrombosis is a significant contributor to cardiovascular events.
Purpose of the Study:
- To investigate the anti-thrombotic effects of Mumefural (MF) in vivo.
- To evaluate MF's impact on blood flow and thrombus formation in a rat model.
- To explore the molecular mechanisms underlying MF's protective effects.
Main Methods:
- Induction of arterial thrombosis using ferric chloride (FeCl3) in Sprague-Dawley rats.
- Administration of MF (0.1, 1, or 10 mg/kg) prior to thrombosis induction.
- Measurement of time to occlusion, thrombus weight, and assessment of vascular damage.
- Analysis of inflammatory markers including NF-κB, TLR4, TNF-α, and IL-6.
- Evaluation of platelet activation markers P-selectin and E-selectin expression.
- Assessment of MF bioavailability in rat plasma.
Main Results:
- MF significantly inhibited FeCl3-induced arterial thrombosis and thrombus formation.
- MF treatment improved blood flow and reduced vessel occlusion time.
- MF prevented collagen fiber damage and reduced P-selectin/E-selectin expression.
- MF significantly decreased inflammatory markers (NF-κB, TLR4, TNF-α, IL-6).
- MF exhibited a bioavailability of 36.95% in rat plasma.
Conclusions:
- Mumefural demonstrates significant anti-thrombotic and anti-inflammatory effects in vivo.
- MF's mechanisms involve inhibiting platelet activation and inflammatory pathways.
- MF shows potential as a natural therapeutic agent for improving blood circulation and preventing thrombotic disorders.
- MF is a promising candidate for dietary supplements aimed at enhancing vascular health.
